NEKTAR THERAPEUTICS's ticker is NKTR and the CUSIP is 640268108. A total of 341 filers reported holding NEKTAR THERAPEUTICS in Q2 2019. The put-call ratio across all filers is 2.70 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $83,645 | -62.2% | 140,439 | -63.5% | 0.00% | – |
| Q2 2023 | $221,196 | +71.4% | 384,555 | +109.3% | 0.00% | – |
| Q1 2023 | $129,088 | +27.8% | 183,720 | +310.9% | 0.00% | – |
| Q4 2022 | $101,040 | -83.3% | 44,708 | -76.3% | 0.00% | – |
| Q3 2022 | $605,000 | -11.3% | 188,946 | +5.3% | 0.00% | – |
| Q2 2022 | $682,000 | -88.2% | 179,519 | -83.3% | 0.00% | -100.0% |
| Q1 2022 | $5,777,000 | -48.2% | 1,071,810 | +29.8% | 0.00% | – |
| Q4 2021 | $11,160,000 | +51.3% | 826,052 | +101.1% | 0.00% | -100.0% |
| Q3 2021 | $7,377,000 | +2.1% | 410,682 | -2.5% | 0.00% | 0.0% |
| Q2 2021 | $7,228,000 | +96.9% | 421,246 | +129.5% | 0.00% | – |
| Q1 2021 | $3,671,000 | -67.0% | 183,558 | -72.0% | 0.00% | -100.0% |
| Q4 2020 | $11,136,000 | +85.0% | 655,024 | +80.6% | 0.00% | – |
| Q3 2020 | $6,018,000 | -44.2% | 362,767 | -22.1% | 0.00% | -100.0% |
| Q2 2020 | $10,792,000 | +88.5% | 465,958 | +45.3% | 0.00% | +50.0% |
| Q1 2020 | $5,726,000 | -79.1% | 320,795 | -74.7% | 0.00% | -75.0% |
| Q4 2019 | $27,375,000 | -17.5% | 1,268,281 | -30.4% | 0.01% | -33.3% |
| Q3 2019 | $33,196,000 | -84.1% | 1,822,435 | -69.0% | 0.01% | -53.8% |
| Q2 2019 | $209,437,000 | +271.7% | 5,886,385 | +251.0% | 0.03% | +13.0% |
| Q1 2019 | $56,348,000 | -27.8% | 1,677,048 | -29.4% | 0.02% | -25.8% |
| Q4 2018 | $78,037,000 | -26.8% | 2,374,113 | +35.7% | 0.03% | -13.9% |
| Q3 2018 | $106,632,000 | -9.3% | 1,749,214 | -27.4% | 0.04% | -12.2% |
| Q2 2018 | $117,574,000 | -54.4% | 2,407,813 | -0.8% | 0.04% | -55.4% |
| Q1 2018 | $257,951,000 | +229.8% | 2,427,557 | +85.3% | 0.09% | +228.6% |
| Q4 2017 | $78,216,000 | +342.3% | 1,309,718 | +77.7% | 0.03% | +300.0% |
| Q3 2017 | $17,685,000 | +16.0% | 736,845 | -5.5% | 0.01% | +16.7% |
| Q2 2017 | $15,242,000 | +9.5% | 779,597 | +31.5% | 0.01% | -14.3% |
| Q1 2017 | $13,917,000 | +84.2% | 592,932 | -3.7% | 0.01% | +75.0% |
| Q4 2016 | $7,556,000 | +82.5% | 615,741 | +155.5% | 0.00% | +100.0% |
| Q3 2016 | $4,140,000 | +90.3% | 240,975 | +57.6% | 0.00% | +100.0% |
| Q2 2016 | $2,176,000 | -23.0% | 152,900 | -25.6% | 0.00% | -50.0% |
| Q1 2016 | $2,827,000 | -44.6% | 205,608 | -32.2% | 0.00% | 0.0% |
| Q4 2015 | $5,106,000 | +52.2% | 303,038 | -1.0% | 0.00% | +100.0% |
| Q3 2015 | $3,355,000 | -25.4% | 306,076 | -14.8% | 0.00% | -50.0% |
| Q2 2015 | $4,495,000 | +18.4% | 359,324 | +4.1% | 0.00% | 0.0% |
| Q1 2015 | $3,797,000 | -21.6% | 345,110 | +10.5% | 0.00% | 0.0% |
| Q4 2014 | $4,842,000 | +65.7% | 312,407 | +29.0% | 0.00% | 0.0% |
| Q3 2014 | $2,923,000 | -63.6% | 242,100 | -61.4% | 0.00% | -33.3% |
| Q2 2014 | $8,037,000 | +47.6% | 626,883 | +39.6% | 0.00% | +50.0% |
| Q1 2014 | $5,444,000 | -0.7% | 449,119 | -7.0% | 0.00% | 0.0% |
| Q4 2013 | $5,484,000 | -14.7% | 483,090 | -21.5% | 0.00% | -50.0% |
| Q3 2013 | $6,429,000 | +150.6% | 615,325 | +177.0% | 0.00% | +300.0% |
| Q2 2013 | $2,565,000 | – | 222,108 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Camber Capital Management LP | 2,000,000 | $67,200,000 | 3.35% |
| First Light Asset Management, LLC | 763,403 | $25,650,000 | 3.33% |
| BRIDGER MANAGEMENT, LLC | 1,238,489 | $41,613,000 | 3.29% |
| Rhenman & Partners Asset Management AB | 734,445 | $24,677,000 | 2.89% |
| BB BIOTECH AG | 2,020,676 | $67,895,000 | 1.71% |
| Gs Investments, Inc. | 54,200 | $1,821,120,000 | 1.43% |
| Artal Group S.A. | 900,000 | $30,240,000 | 1.24% |
| Cormorant Asset Management, LP | 500,000 | $16,800,000 | 1.14% |
| TOBAM | 640,547 | $21,522,000 | 1.09% |
| Bellevue Group AG | 430,026 | $14,449,000 | 0.80% |